Copy Link Print Information

Doxorubicin

(Synonyms: Hydroxydaunorubicin)
698 Cited Publications
Kundenbewertung

Based on 698 publication(s) in Google Scholar

Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • CAS. Nr.: 23214-92-8
  • Formel: C27H29NO11
  • Molecular Weight:543.52
  • Speicherung:

    4°C, sealed storage, away from moisture and light

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

  • Doxorubicin Chemical Structure
    Doxorubicin Chemical Structure
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
CAS. Nr.: 23214-92-8
Größe
Preis
Verfügbarkeit
Menge
Amount: USD 0.00
Please select quantity
or
or

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Doxorubicin:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Finden Sie Ihren Händler vor Ort Your local distributor: Hycultec GmbHHycultec
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Doxorubicin

More
Customer Validation & Images
IFIn Vivo Efficacy StudyIHCCell Proliferation/Viability AssayWB
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • WB
  • IF
  • WB
  • IHC
  • IF
  • WB
  • WB
  • WB
  • IF
  • WB
  • WB
  • IF

Alle ADC Payloads Isoform-spezifische Produkte anzeigen

More

Alle Antibiotic Isoform-spezifische Produkte anzeigen

More

Alle Topoisomerase Isoform-spezifische Produkte anzeigen

More

Alle AMPK Isoform-spezifische Produkte anzeigen

More

Alle HIV Isoform-spezifische Produkte anzeigen

More
Keywords
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Einloggen
Registrieren
Sign in to MedChemExpress
Neuen Account Registrieren

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Doxorubicin Chemical Structure
    Doxorubicin Chemical Structure
    1/16
  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 May 9;23(1):83. [Abstract]

    Customer Validation
     Exhausted T-cells (NExT) loaded with Doxorubicin (5–50 nM; 48 h) significantly reduces the viability of SUM159 cells.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2024 May 11:38:384-398. [Abstract]

    Customer Validation
     Doxorubicin hydrochloride (10 μM; 3-5 days) significantly reduces the viability of lung cancer organoid-2 (LCO-2) and LCO-3, while showing no significant effect on LCO-1 viability.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]

    Customer Validation
     The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     SUDHL-4, OCI-Ly3 cells were treated with different concentrations of FKB (Flavokawain B; HY-N2132; 1.25–20 µg/ml) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability (OD value at 490 nm) was measured using the MTS assay. *p < 0.05, #p < 0.01, †p < 0.001, and ‡p < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     Raji, and Jeko-1 cells were treated with different concentrations of FKB (Flavokawain B; HY-N2132; 1.25–20 µg/ml) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability (OD value at 490 nm) was measured using the MTS assay. *p < 0.05, #p < 0.01, †p < 0.001, and ‡p < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     FKB (Flavokawain B; HY-N2132) decelerates lymphoma growth of SUDHL-4 cells in a xenograft animal model in vivo. BALB/c nude mice were subcutaneously inoculated with 5 × 106 SUDHL-4 cells on day 0. Mice were randomly divided into four groups (n = 5 per group) and treatment with vehicle or the corresponding drugs (FKB (HY-N2132; 0.75, 1.5 mg/kg; every four days; IP), or Doxorubicin (HY-15142A; 5 mg/kg; once a week; IP)) was initiated on day 3. The tumor volume was recorded at indicated days. *p < 0.05 and #p < 0.01 versus the control. Tumors were weighed and photographed after removing from each mouse at the end of the experiment (on day 29). *p < 0.05, #p < 0.01, and †p < 0.001 versus the control.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     SUDHL-4 and OCI-Ly3 cells were treated with FKA (Flavokawain A; HY-N2420; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     Raji and Jeko-1 cells were treated with FKA (Flavokawain A; HY-N2420; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     SUDHL-4 and OCI-Ly3 cells were treated with FKC (Flavokawain C; HY-N2445; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     Raji and Jeko-1 cells were treated with FKC (Flavokawain C; HY-N2445; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 23 October 2021.

    Customer Validation
     Cell viability after incubated with free DOX under normoxia and hypoxia at various DOX (Doxorubicin) (0.65-20 μg/mL) concentrations for 24 h determined by MTT assay.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2020 Sep;22(9):1056-1063. [Abstract]

    Customer Validation
     UFMylation of endogenous p53 was analysed by western blot in HCT116 p53+/+ cells depleted of UFL1 or DDRGK1 upon DNA damage induced by doxorubicin (doxo; 1 µM; 24 h) or etoposide (eto; 25 µg ml−1; 12 h).

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]

    Customer Validation
     Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Representative images of immunofluorescence staining of KRT8 of CM318 and UCH1 cell line.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]

    Customer Validation
     Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Western blotting analysis and quantification of KRT8 protein expression (normalized to GAPDH expression).

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2019 Jan:130:557-567. [Abstract]

    Customer Validation
     Representative pictures of Live/Dead staining of effects of 7,8-DHF on high dose of Dox-induced cell death and MMP reduction of H9c2 cells.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Sep;23(9):6034-6047. [Abstract]

    Customer Validation
     Effects of YWPC (50 mg/L for 24 h) on DOX (5 μM for 24 h)-induces dissipation of mitochondrial membrane potential measured in H9C2 cells loaded with JC-1 using fluorescence microscopy.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139. [Abstract]

    Customer Validation
     One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499. [Abstract]

    Customer Validation
     Immunoblotting for EZH2 in lysates of immortalized mouse podocytes after treatment with Adriamycin (300 ng/mL) for 48 hours (n=6).

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Sep 19;37(1):232. [Abstract]

    Customer Validation
     Immunoblotting shows that both P-gp protein expression is significantly decreased in 24 h after US exposure in MCF-7/ADR and HEPG2/ADM cells.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nanoscale Res Lett. 2018 Nov 3;13(1):350. [Abstract]

    Customer Validation
     Fluorescence microscopy of images of fixed 4T1-luc2-GFP breast cancer cells treated with Doxorubicin (DOX) after 48-h exposure. Scale bars indicate 100 μm. Blue nuclear stain: DAPI; green (transfected cell line): GFP; red (intrinsic molecular fluorescence): DOX

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 Aug:36:108-116. [Abstract]

    Customer Validation
     PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), CDDP (for 24 h) and Doxorubicin (for 10 h) as indicated, followed by immunoblotting with the antibodies.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;42(3):965-973. [Abstract]

    Customer Validation
     U937 cells are treated with Thapsigargin (TG, 1 μM), NSC 125973 (PTX, 5nM) as well as Doxorubincin (DOX, 1 μM) for 12 hours and the indicated proteins are detected by Western blot.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Med. 2016 May;22(5):547-56. [Abstract]

    Customer Validation
     Immunofluorescent staining for α-actinin (ACTN2) and cardiac troponin T (TNNT2) to demonstrate sarcomeric organization in hiPSC–CMs derived from patients who do not experience Doxorubicin–induced cardiotoxicity (DOX) versus those who do experience Doxorubicin-induced cardiotoxicity (DOXTOX) after 24 h treatment with Doxorubicin. Scale bar, 20 µm.

  • Doxorubicin